Abeona Therapeutics Inc. (ABEO) Reaches New 12-Month High at $15.95
Abeona Therapeutics Inc. (NASDAQ:ABEO)’s share price reached a new 52-week high during mid-day trading on Friday . The stock traded as high as $15.95 and last traded at $16.05, with a volume of 2,713,195 shares traded. The stock had previously closed at $14.00.
Several equities analysts recently issued reports on the company. Maxim Group set a $17.00 price target on Abeona Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, August 16th. HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Abeona Therapeutics in a research report on Friday, September 8th. Royal Bank Of Canada began coverage on Abeona Therapeutics in a research report on Thursday. They set an “outperform” rating and a $23.00 price target on the stock. Zacks Investment Research lowered Abeona Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, August 16th. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $21.00 price objective on shares of Abeona Therapeutics in a research report on Tuesday, June 6th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company. Abeona Therapeutics presently has an average rating of “Buy” and a consensus target price of $18.50.
The firm’s market cap is $692.94 million. The firm has a 50 day moving average price of $10.28 and a 200 day moving average price of $7.02.
Abeona Therapeutics (NASDAQ:ABEO) last released its earnings results on Tuesday, August 15th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.07). The business had revenue of $0.22 million for the quarter, compared to the consensus estimate of $0.21 million. Abeona Therapeutics had a negative net margin of 2,746.38% and a negative return on equity of 26.66%. Equities research analysts anticipate that Abeona Therapeutics Inc. will post ($0.68) earnings per share for the current year.
Several institutional investors and hedge funds have recently added to or reduced their stakes in ABEO. Bank of New York Mellon Corp grew its stake in shares of Abeona Therapeutics by 125.8% during the first quarter. Bank of New York Mellon Corp now owns 41,929 shares of the biopharmaceutical company’s stock valued at $210,000 after buying an additional 23,358 shares during the last quarter. Private Advisor Group LLC grew its stake in shares of Abeona Therapeutics by 50.0% during the first quarter. Private Advisor Group LLC now owns 21,005 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 6,999 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of Abeona Therapeutics by 17.4% during the first quarter. Wellington Management Group LLP now owns 204,590 shares of the biopharmaceutical company’s stock valued at $1,023,000 after buying an additional 30,300 shares during the last quarter. Laurion Capital Management LP bought a new position in shares of Abeona Therapeutics during the first quarter valued at approximately $277,000. Finally, Segantii Capital Management Ltd grew its stake in shares of Abeona Therapeutics by 564.6% during the first quarter. Segantii Capital Management Ltd now owns 33,894 shares of the biopharmaceutical company’s stock valued at $169,000 after buying an additional 28,794 shares during the last quarter. 38.24% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: “Abeona Therapeutics Inc. (ABEO) Reaches New 12-Month High at $15.95” was originally reported by Daily Political and is the property of of Daily Political. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2017/09/16/abeona-therapeutics-inc-abeo-reaches-new-12-month-high-at-15-95.html.
About Abeona Therapeutics
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).
Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.